EAGLE PHARMACEUTICALS, INC.
eagleus.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 8, 2023. Its latest SEC filing is a SCHEDULE 13G from Aug 14, 2025.
10-Q for Q2 FY2023, filed Aug 8, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops and sells injectable medicines for oncology and acute-care use to hospitals and surgery centers, through its own sales team and marketing partners.
10-K for FY2022, filed Mar 23, 2023Our science-based business model has a proven track record with the U.S. Food and Drug Administration ("FDA") approval and commercial…View ↗
Retain commercial rights in the United States and selectively partner outside of the United States. In general, we believe that we can…View ↗
BARHEMSYS and BYFAVO are sold directly to wholesalers, hospitals and surgery centers through a third-party logistics partner.View ↗
How Did They Make Money?
Eagle earns money selling medicines to commercial partners and end users; customers pay after shipment or delivery, generally within 30 to 75 days, with longer terms for some wholesalers’ initial launch orders.
10-K for FY2022, filed Mar 23, 2023Product revenue - The Company recognizes net revenue on sales to its commercial partners and to end users. In each instance, revenue is…View ↗
$316.6M
-
10-K for FY2022, filed Mar 24, 2023
$316.6M ↗
Who Were Their Customers?
The company markets products through its own sales team and partners. BARHEMSYS and BYFAVO are sold to wholesalers, hospitals and surgery centers through a third-party logistics partner; Teva markets Bendeka, and SymBio markets Treakisym in Japan.
10-K for FY2022, filed Mar 23, 2023Our science-based business model has a proven track record with the U.S. Food and Drug Administration ("FDA") approval and commercial…View ↗
BARHEMSYS and BYFAVO are sold directly to wholesalers, hospitals and surgery centers through a third-party logistics partner.View ↗
Other than products subject to existing commercialization arrangements, we commercialize our product portfolio in the United States and…View ↗
10-K for FY2022, filed Mar 23, 2023
Year Ended December 31, 2022 2021 2020 Total revenues Teva 33 % 66 % 67 % Customer A 19 % 7 % 10 % Customer B 12 % 9 % 5 % Customer C 12 %…View ↗
Did Revenues Turn Into Profits?
Yes. It kept 11 cents of every revenue dollar as net income in FY2022 and turned 16 cents into free cash flow.
10-K for FY2022, filed Mar 24, 2023
$90.4MView ↗
10-K for FY2022, filed Mar 24, 2023
$35.6MView ↗
10-K for FY2022, filed Mar 24, 2023
$50.5MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2023, filed Aug 8, 2023
$5.2MView ↗
- ▲ Now profitable
- vs −$9.5M in Q2 FY2022
-
Nov 27, 2024
Company replaced its auditor amid planned financial-statement restatements
EY was dismissed and BDO was engaged to audit the company’s fiscal periods; previously filed statements were set for restatement.
Sources
8-K, filed Nov 27, 2024
On November 21, 2024, Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”), dismissed Ernst & Young LLP (“EY”), the…View ↗
-
Nov 15, 2024
Company announced a plan to delist from Nasdaq
Its shares had been suspended from Nasdaq trading and were trading on the OTC Expert Market.
Sources
8-K, filed Nov 15, 2024
On November 15, 2024, Eagle Pharmaceuticals, Inc. (the “Company”) notified The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to file…View ↗
-
Nov 12, 2024
Company appointed a new chief financial officer
Christopher Krawtschuk replaced interim CFO Steven Ratoff, who remained a director.
Sources
8-K, filed Nov 12, 2024
On November 8, 2024, the Board of Directors (the “Board”) of Eagle Pharmaceuticals, Inc. (the “Company”) appointed Christopher Krawtschuk…View ↗
-
Oct 2, 2024
Company said FY2022 and interim statements should be restated
The audit committee cited a PEMFEXY sale whose revenue had been recorded before certain criteria were met.
Sources
8-K, filed Oct 2, 2024
On September 27, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company, based on the recommendation…View ↗
Grew. Revenue grew 48% in 4 years, from $213.3M in FY2018 to $316.6M in FY2022, about 10% a year.
Broader marketed portfolio
The older report centered on Ryanodex, Belrapzo and Bendeka; the latest report also lists PEMFEXY, vasopressin, Treakisym, BARHEMSYS and BYFAVO, including products added through the Acacia acquisition.
10-K for FY2019, filed Mar 2, 2020 10-K for FY2022, filed Mar 23, 2023
Who Did They Compete With?
Competes with Fresenius Kabi and Pfizer
10-K for FY2022, filed Mar 23, 2023Fresenius Kabi supplies Propofol globally and Pfizer currently markets Midazolam. See “Business—Competition” and “Risk Factors — We face…View ↗
Loading...
